Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis

Hüseyin Saadettin Uslusoy, Selim Giray Nak, Macit Gülten

Hüseyin Saadettin Uslusoy, Selim Giray Nak, Macit Gülten, Department of Gastroenterology, İzmit Seka State Hospital, Kocaeli 41000, Turkey

Author contributions: Uslusoy HS performed the research; Nak SG wrote and translated the manuscript; Gülten M designed the research and did the revision.

Correspondence to: Hüseyin Saadettin Uslusoy, MD, Department of Gastroenterology, İzmit Seka State Hospital, Kocaeli 41000, Turkey. huslusoy.25@hotmail.com

Telephone: +90-262-3223469 Fax: +90-262-3248136

Received: March 9, 2011 Revised: June 6, 2011 Accepted: July 18, 2011

Published online: August 27, 2011

Abstract

AIM: To evaluate certain anthropometric, clinical and laboratory features indicating liver fibrosis in nonalcoholic steatohepatitis and to establish the noninvasive markers for liver fibrosis.

METHODS: Eighty-one patients (40 male, 41 female) who were diagnosed with fatty liver by ultrasonographic examination and fulfilled the inclusion criteria participated in the study. Anamnesis, anthropometric, clinical and laboratory features of all cases were recorded and then liver biopsy was performed after obtaining patient consent. Steatosis, necroinflammation and liver fibrosis were examined according to age ≥ 45, gender, body mass index, central obesity, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 1, γ-glutamyltransferase (GGT)/ALT > 1, platelet count, insulin, c-peptide levels and the presence of hypertension, diabetes, hypertriglyceridemia and insulin resistance.

RESULTS: Eighty-one patients with non-alcoholic steatohepatitis (NASH) enrolled in the study. 69 of 81 patients were diagnosed with NASH, 11 were diagnosed with simple fatty liver and 1 was diagnosed with cirrhosis. AST/ALT > 1, GGT/ALT > 11, high serum ferritin and fasting insulin levels, the presence of diabetes, hypertension, hypertriglyceridemia and insulin resistance seemed to enhance the severity of steatosis, necroinflammation and fibrosis but these results were not statistically significant.

CONCLUSION: Liver steatosis and fibrosis can occur in individuals with normal weight. There was no significant concordance between severity of liver histology and the presence of predictors for liver fibrosis including metabolic risk factors.

© 2011 Baishideng. All rights reserved.

Key words: Liver fibrosis; Predictors; Nonalcoholic fatty liver disease; Steatohepatitis

Peer reviewers: Neil Louis Julie, MD, Gastroenterology and Hepatology, 7609 Exeter Rd, Bethesda, MD 20814, United States; Ilker Tasci, Associate Professor, Gulhane School of Medicine, Department of Internal Medicine, 06018 Etlik, Ankara, Turkey; Waka Ohishi, MD, PhD, Senior Scientist, Chief, Division of Clinical Laboratories, Department of Clinical Studies, Radiation Effects Research Foundation, 5-2 Hijiyayama Park, Minami-ku, Hiroshima 732-0815, Japan

Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 Available from: URL: http://www.wjgnet.com/1948-5182/full/v3/i8/219.htm DOI: http://dx.doi.org/10.4254/wjh.v3.i8.219

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is a hepatic pathology which includes fat accumulation and inflammation in hepatocytes accompanied by fibrosis in various degrees, with negligible or no alcohol consumption.
This entity may progress to cirrhosis and liver failure[1]. Although NAFLD is supposed to be in association with certain metabolic disorders like obesity, diabetes and hyperlipidemia, it can also occur in lean individuals and those without diabetes[2,3]. The natural progression of fatty liver is not definitely estimated previously. While approximately 7%-37.6% of patients with non-alcoholic steatohepatitis (NASH) may have advanced fibrosis and 20% of patients with NASH may silently progress to cirrhosis, fatty liver should not always be considered as an innocent condition[4-9]. Due to the difficulties in extensive application of liver biopsy, many anthropometric, clinical and laboratory features in NASH patients were investigated for their currency and worthiness in the prediction of liver fibrosis. Our aim is to research and reveal the validity, accuracy and convenience of certain anthropometric, clinical and laboratory features to predict liver fibrosis and their concordance with liver histology.

**MATERIALS AND METHODS**

**Patients**
EIGHTY-ONE patients, diagnosed with fatty liver as mild, moderate and severe by ultrasonographic examination and with an elevation in alanine aminotransferase (ALT) levels of at least 1.5 fold of the normal range and persistent liver steatosis, were enrolled in the study in Uludag University Gastroenterology Division. After complete anthropometric, clinical and laboratory assessments, liver biopsy was performed. Exclusion criteria were alcohol consumption ≥ 20 g/d, pregnancy, positive tests indicating the presence of hepatitis B and C virus, autoimmune liver diseases, hemochromatosis, Wilson’s disease, α1 antitrypsin deficiency, primary biliary cirrhosis, primary sclerosing cholangitis and toxic liver diseases. Data handling and liver biopsy were performed with patient consent. The study was approved by the hospital ethics committee.

**Laboratory studies**
All cases underwent liver examination by ultrasonography and subsequently anamnesis; anthropometric, clinical, complete blood count and biochemical assessments were performed. Biochemical evaluation consisted of ALT, aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), alkaline phosphatase (ALP), bilirubin, albumin, high-density lipoprotein (HDL)-cholesterol, triglycerides, fasting glucose and insulin levels and oral glucose tolerance test. Anthropometric measurements included height, weight, body mass index (BMI), waist and hip circumferences and waist/hip ratio values. Diagnosis of obesity was dependent on World Health Organization (WHO) criteria[9]. American Diabetes Association criteria were used to signify type 2 diabetes, impaired glucose intolerance and impaired fasting glycaemia. Patients on oral antidiabetics or insulin therapy were accepted as diabetics. Hypertension was recognized when resting blood pressure was ≥ 140/90 mmHg or when patients were on antihypertensive drug therapy. Triglycerides ≥ 1500 mg/L were accepted as hypertriglyceridaemia. The measurement of insulin resistance was made using homeostatic model assessment (HOMA) method and patients were classed as insulin resistant while HOMA value was ≥ 2.70. ALT levels 1.5 or more times the upper normal values marked an elevation. The diagnosis of metabolic syndrome was made using WHO criteria[9, 10]. BMI ≥ 30 kg/m², waist/hip circumference ratio > 0.90 in men and > 0.85 in women, fasting blood glucose ≥ 1100 mg/L, overt diabetes, presence of impaired glucose tolerance and/or IR, triglycerides ≥ 1500 mg/L, HDL-cholesterol < 400 mg/L in men and < 500 mg/L in women, arterial blood pressure ≥ 140/90 mmHg and presence of microalbuminuria. Patients had at least three of these criteria to be diagnosed with metabolic syndrome. The study was approved by the hospital ethics committee.

**Pathology**
All 81 patients underwent liver biopsy according to the severity of clinical and laboratory features and patient consent. Liver biopsy specimens were examined by liver pathologists in the Department of Pathology at the Medical Faculty in Uludag University. Necroinflammation and fibrosis in liver were evaluated using the histopathological criteria defined by Brunt et al.[10]. Diagnosis of NASH was dependent on steatosis (mild: < 33% of lobules, moderate: 33%-66% of lobules and severe: > 66% of lobules) and 2 of the 3 features: (1) necroinflammation with mononuclear cells and/or polymorphonuclear leukocytes; (2) ballooning degeneration of hepatocytes, Mallory bodies; and (3) pericellular, perisinusoidal and/or bridging fibrosis. Steatosis and necroinflammation were categorized as grade 1, 2 and 3 and fibrosis as grade 1, 2, 3 and 4 (cirrhosis).

**Statistical analysis**
Statistical significance was not reached due to the small number of patients and statistical evaluation and P values were not available. Evaluations were performed using percentage values. Hence, patient features were evaluated according to their percentage values.

**RESULTS**

**Anthropometric, clinical and laboratory results**
EIGHTY-ONE patients (40 male, 41 female) who were diagnosed with fatty liver by ultrasonographic examination participated in the study at Uludag University Gastroenterology Division. All patients underwent liver biopsy. 69 (35 male, 34 female) of 81 patients were diagnosed with NASH, 11 (4 male, 7 female) were diagnosed with simple fatty liver and 1 (male) was diagnosed with cirrhosis. Initial characteristics of all patients were obtained and recorded as shown in Table 1. We used the most pronounced independent risk factors such as age ≥ 45 years, gender, BMI > 30 kg/m², central obesity (waist/hip ratio ≥ 0.85 in women, fasting blood glucose ≥ 1100 mg/L, overt diabetes, presence of impaired glucose tolerance and/or IR, triglycerides ≥ 1500 mg/L, HDL-cholesterol < 400 mg/L in men and < 500 mg/L in women, arterial blood pressure ≥ 140/90 mmHg and presence of microalbuminuria. Patients had at least three of these criteria to be diagnosed with metabolic syndrome. The study was approved by the hospital ethics committee.
This table shows that numbers of non obese patients are much higher than obese patients and 33.4% of non-alcoholic steatohepatitis patients have no metabolic syndrome. BMI: Body mass index; HDL: High-density lipoprotein.

Table 1 General aspects of all non-alcoholic steatohepatitis cases n (%) 

| Nonalcoholic steatohepatitis (n = 70) | 
|--------------------------------------|
| Average age (yr) | 47.9 ± 8.74 |
| Gender (male/female) | 36/34 |
| Hepatomegaly | 16 (23.9) |
| BMI (kg/m²) | 30.4 ± 4.79 |
| Normal weight (BMI < 24.9 kg/m²) | 3 (4.30) |
| Overweight (BMI = 25-29.9 kg/m²) | 34 (48.5) |
| Obese (BMI = 30-39.9 kg/m²) | 29 (41.4) |
| Morbid obese (BMI > 40 kg/m²) | 4 (5.80) |
| Waist/hip cir (E > 0.90, K > 0.85) | 49 (71) |
| Systolic blood pressure (mmHg) | 124 ± 16.2 |
| Diastolic blood pressure (mmHg) | 75.6 ± 11.9 |
| Hypertension | 21 (30.4) |
| HDL-cholesterol (mg/dL) | 46.3 ± 8.07 |
| Low-HDL-cholesterol | 28 (40.5) |
| Triglycerides (mg/dL) | 163 ± 79.5 |
| Hypertriglyceridemia | 36 (52.1) |
| Fasting glucose (mg/dL) | 107 ± 26.2 |
| Diabetes mellitus | 20 (28.8) |
| Fasting insulin (μU/mL) | 16.6 ± 13.0 |
| Homeostatic model assessment-insulin resistance value | 3.91 ± 2.45 |
| Fasting c-peptide | 4.35 ± 2.15 |
| Aspartate aminotransferase (U/L) | 48.2 ± 23.9 |
| Alanine aminotransferase (U/L) | 76.2 ± 35.2 |
| Gama glutamyl transpeptidase (U/L) | 59.2 ± 46.8 |
| Alkaline phosphatase (U/L) | 93.4 ± 32.3 |
| Insulin resistance | 30 (43.4) |
| Metabolic syndrome | 46 (66.6) |

> 0.90 in men and > 0.85 in women, AST/ALT > 1, GGT/ALT > 1, platelet count, fasting serum levels of ferritin, c-peptide and insulin and presence of hypertension, diabetes, hypertriglyceridemia and insulin resistance. Table 1 shows that the numbers of normal and overweight patients were higher than those of obese and morbidly obese patients. This indicates that the risk for liver steatosis could be higher when BMI values exceed 25 kg/m². Prevalences of other components of metabolic syndrome were not significantly increased, as stated in Table 1. These results indicate that NASH could occur in patients with only one risk factor or even in patients without any risk factors.

Although the simple fatty liver group is small (11 patients), we determined that two patients had 2, seven patients had 3, one patient had 4 and one patient had 5 risk factors. These results have shown that the presence and numbers of metabolic risk factors did not give information about liver histology. It seems that discrimination between NASH and simply fatty liver will not be made according only to clinical, epidemiological, anthropometrical or laboratory results.

Furthermore, the presence of predictors for liver fibrosis were also searched for in patients with simple fatty liver. However, in patients with age ≥ 45, obesity, hypertension, diabetes and hypertriglyceridemia, it seemed to be increased but these results were not significant.

Table 2 shows that female gender, age > 45 years seem to have severe steatosis and necroinflammation. Interestingly, patients with normal BMI seem to have severe steatosis and necroinflammation. However, AST/ALT > 1, GGT/ALT > 1 and low platelet count, increase in fasting serum ferritin, insulin and c-peptide levels and presence of metabolic risk factors (diabetes, hypertriglyceridemia, hypertension and insulin resistance) seem to increase severe steatosis and necroinflammation but due to the small number of cases, these results are not significant.

Table 3 shows that gender and age > 45 did not seem to influence the development of fibrosis significantly. Patients with normal BMI seemed to have severe fibrosis but because of the small number of cases, these results were not significant. Central obesity, AST/ALT > 1, GGT/ALT > 1, elevated serum ferritin and fasting insulin levels, presence of hypertension, diabetes, hypertriglyceridemia and insulin resistance seemed to increase fibrosis but these findings were not significant. We diagnosed one patient with cirrhosis who had normal AST/ALT and AST/GGT ratio, normal platelet count and serum ferritin, fasting insulin and c-peptide levels. This patient had no metabolic risk factors apart from diabetes.

**Histopathology**

The detailed features of liver histology of our 81 cases were examined using the presence of “predictors for liver fibrosis”. Tables 2 and 3 present the influences of predictors on liver histology in our 70 NASH cases. The remaining 11 patients were diagnosed with simple fatty liver.

**DISCUSSION**

In the present study, we aimed to reveal simple, confident and feasible noninvasive parameters to assign the severity of nonalcoholic steatohepatitis. General aspects of our patients are presented in Table 1.

Advanced obesity was stated as a risk factor for the development of liver fibrosis by Sobhonslidsuk et al [1], Ong et al [12] and Ratziu et al [13]. Recent studies revealed that the people with normal body weight but high visceral fat ratio (central obesity) could have NAFLD, metabolic syndrome and insulin resistance [14]. Sobhonslidsuk et al [1] and Cheung et al [15] stated that abdominal obesity correlated only with liver inflammation and so waist circumference predicts metabolic risk condition with the most significance. Angelico et al [16] and Marchesini et al [17] found a correlation between various degrees of liver steatosis and BMI but we did not detect any relationship between steatosis and BMI (Table 2). Boza et al [18] found no significant association between BMI and histological changes. In the latest study, high HOMA-IR values and ALT levels were the only independent predictors of NASH. Gholam et al [19] stated that except for BMI and hyperglycemia, insulin resistance and the metabolic syndrome were associated with the presence of NASH and fibrosis. Rocha...
said that the prevalence of NAFLD was 2.3% in 199 patients with central obesity. Nevertheless, we observed no connection between central obesity and fibrosis/necroinflammation. It is a remarkable point that necroinflammation and fibrosis could progress even in patients with normal weight (Tables 2 and 3).

Females aged over 45 years were considered to influence liver histology in nonalcoholic steatohepatitis. Daryani et al[21] and Shimada et al[22] have found that females over 55 had a relationship with liver steatosis and advanced fibrosis and other metabolic parameters (e.g. obesity, diabetes, hypertension) but these were not statistically significant predictors[23]. Harrison et al[24] and Yatsuji et al[25] said that advanced age was related to advanced fibrosis. Singh et al[26] and Liew et al[27] found that older females were identified as independent predictors of fibrotic severity. Ong et al[12], Helling et al[28] and Arun et al[29] stated that male gender was associated with NASH. Prashanth et al[30] said that older age, duration of diabetes mellitus, degree of glycemic control, BMI, waist circumference and family history of diabetes mellitus did not predict the presence or severity of NAFLD or fibrosis. In our study, age over 45 years and gender did not seem to have more severe steatosis/necroinflammation and fibrosis (Tables 2 and 3).

Elevated ALT and AST levels were assessed as remarkable markers for NASH and liver fibrosis. Hossain et al[31] found that diabetes mellitus and aminotransferase levels are independent predictors of fibrosis in NAFLD. Chavarría-Arciniega et al[32] stated that fibrosis showed correlation only with AST. Rodríguez-Hernández et al[33] stressed that ALT was correlated with inflammation and fibrosis.

### Table 2  Predictors of liver fibrosis and liver histology (steatosis and necroinflammation) in patients with nonalcoholic steatohepatitis

|                     | Steatosis (n = 70) | Necroinflammation (Grade) (n = 70) |
|---------------------|-------------------|-----------------------------------|
|                     | Mild (%) | Moderate (%) | Severe (%) | Mild (%) | Moderate (%) | Severe (%) |
| Gender              |          |              |            |          |              |            |
| Male                | 38.9     | 38.9         | 22.1       | 36.1     | 55.5         | 8.3        |
| Female              | 41.2     | 35.3         | 23.5       | 20.6     | 64.7         | 14.7       |
| Age (yr)            |          |              |            |          |              |            |
| > 45                | 35.4     | 37.5         | 27.0       | 25.0     | 62.5         | 12.5       |
| < 45                | 45.4     | 36.3         | 18.1       | 36.3     | 59.0         | 4.5        |
| Body mass index (kg/m²) |        |              |            |          |              |            |
| 18.5-24.9           | 0       | 66.6         | 34.4       | 33.3     | 33.4         | 33.3       |
| 25.0-29.9           | 34.2     | 42.9         | 22.9       | 31.4     | 60.0         | 8.6        |
| 30.0-39.9           | 50.0     | 21.5         | 28.5       | 32.1     | 53.6         | 14.3       |
| > 40                | 25.0     | 75.0         | 0          | 50.0     | 50.0         | 0          |
| Central obesity     |          |              |            |          |              |            |
| +                   | 40.0     | 38.0         | 22.0       | 28.5     | 61.2         | 10.2       |
| -                   | 35.0     | 35.0         | 30.0       | 28.5     | 57.1         | 14.2       |
| AST/ALT > 1         | 40.0     | 20.0         | 40.0       | 20.0     | 40.0         | 40.0       |
| AST/ALT < 1         | 37.5     | 39.0         | 23.4       | 29.6     | 60.9         | 9.3        |
| GGT/ALT > 1         | 36.3     | 27.2         | 36.3       | 31.8     | 50.0         | 18.1       |
| GGT/ALT < 1         | 38.2     | 42.5         | 19.1       | 25.5     | 65.9         | 8.6        |
| Platelet count      |          |              |            |          |              |            |
| Low                 | 35.4     | 0            | 66.6       | 33.4     | 33.3         | 33.4       |
| Normal              | 39.3     | 37.8         | 22.7       | 36.3     | 53.0         | 10.6       |
| Ferritin            |          |              |            |          |              |            |
| Elevated            | 0        | 33.4         | 66.6       | 0        | 33.4         | 66.6       |
| Normal              | 39.3     | 37.8         | 22.7       | 28.7     | 62.1         | 10.6       |
| Fasting insulin     |          |              |            |          |              |            |
| Elevated            | 14.4     | 28.5         | 57.1       | 14.4     | 71.4         | 14.4       |
| Normal              | 42.0     | 35.5         | 22.5       | 30.6     | 62.0         | 11.2       |
| Fasting c-peptid    |          |              |            |          |              |            |
| Elevated            | 31.2     | 37.5         | 31.2       | 15.6     | 71.8         | 12.5       |
| Normal              | 45.9     | 35.1         | 18.9       | 37.8     | 51.3         | 10.8       |
| Hypertension        |          |              |            |          |              |            |
| Present             | 38.1     | 33.4         | 28.5       | 19.0     | 62.0         | 19.0       |
| Absent              | 38.7     | 38.7         | 22.4       | 32.6     | 59.2         | 8.2        |
| Diabetes            |          |              |            |          |              |            |
| Present             | 38.1     | 33.4         | 28.5       | 23.8     | 57.1         | 14.2       |
| Absent              | 36.7     | 38.7         | 24.4       | 28.5     | 61.2         | 10.2       |
| Hypertriglyceridemia|          |              |            |          |              |            |
| Present             | 36.2     | 38.8         | 25.0       | 19.4     | 66.6         | 13.8       |
| Absent              | 41.0     | 35.2         | 23.5       | 38.2     | 52.9         | 8.8        |
| Insulin resistance  |          |              |            |          |              |            |
| Present             | 37.9     | 34.4         | 27.5       | 24.1     | 65.5         | 10.3       |
| Absent              | 40.0     | 40.0         | 20.0       | 50.0     | 40.0         | 10.0       |

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyltransferase.
fibrosis. Prashanth et al\(^\text{[30]}\) also said that serum alanine aminotransferase (ALT) and ALP levels were significantly higher in patients with steatohepatitis. Gholam et al\(^\text{[18]}\) also said that elevated transaminase levels correlated with NASH and fibrosis. However, 46% of their subjects with NASH had normal transaminases. Shi et al\(^\text{[34]}\) denoted that elevated serum level of ALT is an independent predictor of the degree of inflammation but not of steatosis and fibrosis. Nevertheless, recent certain studies expressed that ALT and AST were not reliable markers for NASH or for fibrosis\(^\text{[34,35]}\). Ong et al\(^\text{[12]}\) said that waist/hip ratio and AST were independently associated with advanced fibrosis but in the latest study the majority of the patients with either NASH or advanced fibrosis had normal AST. Nomura et al\(^\text{[36]}\) and Mofrad et al\(^\text{[37]}\) stated that significant liver disease could exist with normal liver enzyme levels. Fracanzani et al\(^\text{[38]}\) also stressed that normal ALT is not a valuable parameter to exclude patients from liver biopsy. We also found that there was no relationship between ALT and AST levels and liver fibrosis. Furthermore, the ratio of AST/ALT higher than 1 was asserted to be a marker for liver fibrosis in NASH. Prashanth et al\(^\text{[30]}\) found that serum AST/ALT ratio was significantly higher in patients with severe fibrosis and, additionally, all patients with severe fibrosis had metabolic syndrome. Gramlich et al\(^\text{[20]}\), Harrison et al\(^\text{[24]}\) and McPherson et al\(^\text{[39]}\) said that the presence of AST/ALT > 1 could exclude liver fibrosis in patients with NAFLD. Myers and Amarapurkar et al\(^\text{[40]}\) revealed that elevation in AST,
ALT levels and AST:ALT > 1 did not show significant association with fibrosis. In the latest study, there was no accurate noninvasive method available that could previously determine the risk of fibrosis in patients with NASH and the elevated levels of transaminases were non-specific with the disease. Hence, liver biopsy remains the gold standard in staging and predicting progression in patients with NASH. Myers\[^{33}\] said that an AST:ALT ratio above 1 might indicate advanced fibrosis; however, its sensitivity was poor. Bahrami \textit{et al.}\[^{40}\] determined that the value of AST/ALT < 1 was present in 65.3% of patients with NAFLD. Shimada \textit{et al.}\[^{25}\] said that the AST:ALT ratio was less specific. In our study, the presence of AST/ALT > 1 seemed to increase steatosis, necroinflammation and fibrosis, but these results were not significant. Furthermore, 20% of patients with AST/ALT > 1 had no fibrosis, the other 20% of patients with AST/ALT > 1 had only slight necroinflammation. In addition, in patients with AST/ALT < 1 the rate of fibrosis was approximately 47%. For example, in our study, one patient with cirrhosis was male, 55 years old and had AST/ALT < 1 but no metabolic syndrome. We observed that the presence of GGT/ALT > 1 also had no relationship with liver histopathology.

Metabolic disorders are considered to influence liver histology in NAFLD\[^{42,43}\]. Prashanth \textit{et al.}\[^{94}\] pointed out that the prevalence of NASH increased with the components of metabolic syndrome. Diabetes mellitus influences liver histology in NAFLD\[^{44}\]. Singh \textit{et al.}\[^{45}\] signified that female gender, BMI, waist:hip ratio, hypercholesterolemia and LDL levels are independent predictors of liver damage in patients with NASH. According to Helling \textit{et al.}\[^{26}\], only increased triglycerides and decreased prealbumin correlated with NASH. Assy \textit{et al.}\[^{46}\] defined hypertriglyceridemia and diabetes as the only risk factors that increase the risk of fatty infiltration in hyperlipidemic patients. Liew \textit{et al.}\[^{47}\] featured that serum cholesterol and low-density lipoprotein cholesterol levels were risk factors associated with gallbladder disease and fatty liver disease. Rodríguez-Hernández \textit{et al.}\[^{48}\] said that diabetes and ALT correlated with histological hepatic changes. Amarapurka \textit{et al.}\[^{49}\] found that diabetes mellitus does not always precede NASH and risk factors like central obesity, dyslipidemia and family history do not forebode the occurrence of NASH in diabetic patients. We also did not detect any significant correlation between individual metabolic risk factors and liver fibrosis in NASH patients (Tables 2 and 3). Moreover, in our study one patient, female and over 45 years, with NASH had no metabolic syndrome, but no significant differences between histological features in NASH patients with or without metabolic syndrome were found. Kang \textit{et al.}\[^{49}\] stated that as low a proportion of 34% of NAFLD patients had metabolic syndrome. Xanthakos \textit{et al.}\[^{50}\] stressed that in morbidly obese adolescents, severe NASH was uncommon and the presence of metabolic syndrome did not distinguish NASH from steatosis alone. In our study, severity of steatosis, necroinflammation and fibrosis were not significant different in NASH patients with metabolic syndrome when compared to those without it.

Fasting c-peptid and insulin levels were asserted to tend to increase in NAFLD. Patients with fatty liver seem to have lower c-peptid and insulin levels than those with NASH\[^{47,51}\]. Recent studies claimed that metabolic risk factors and insulin resistance could influence liver histology\[^{25}\]. Sobhonslidsuk \textit{et al.}\[^{11}\] represented that insulin resistance and elevated visceral fat are risk factors for the presence of NASH. Gholam \textit{et al.}\[^{10}\] said that individuals with NASH had a high level of insulin resistance when compared to those with simple fatty liver. The prevalence of insulin resistance was 85% in the study by Willner \textit{et al.}\[^{52}\]. But Marchesini \textit{et al.}\[^{94}\] revealed the prevalence of insulin resistance in NAFLD was 61%.

However, Dixon \textit{et al.}\[^{53}\] reported that HOMA-IR value, ALT and arterial hypertension were independent predictors for NASH, but they also found that 7.8% of their study patients had NASH even although they had normal AST and HOMA-IR values. Bahrami \textit{et al.}\[^{40}\] found that the rate of insulin resistance was only 54.7% in 53 patients with NASH. Guidorizzi de Siqueira \textit{et al.}\[^{81}\] said that insulin resistance was detected in only 33% of NAFLD patients but there was a high frequency of IR in patients with advanced fibrosis. Sakurai \textit{et al.}\[^{82}\] have specified that only steatosis was significantly and independently associated with elevated HOMA values but there was no similarity association with the grade or stage of NASH.

An interesting observation expressed by Machado \textit{et al.}\[^{76}\] is that the rates of insulin resistance in NAFLD patients could vary from 47% to 98% and in their study, 36% fulfilled three criteria of metabolic syndrome. We detected that, although high c-peptid and insulin levels and presence of insulin resistance seemed to increase the severity of steatosis, steatohepatitis and liver fibrosis, the findings were not significant.

Low platelet count was proposed to be a marker of fibrosis according to Shimada \textit{et al.}\[^{25}\] and Stepanova \textit{et al.}\[^{83}\]. According to the literature, this parameter was not significant alone as a combination of fibrosis markers are advisable\[^{19,59-63}\]. In the present study, the relationship between
low platelet count and the severity of steatosis, steatohepatitis and fibrosis were not significant.

Licata et al[39] pointed out that high serum ferritin level is a risk factor for steatosis. Fracanzani et al[38] said that fibrosis was independently associated with elevated serum ferritin and normal ALT level is not a reliable parameter to exclude patients from liver biopsy. However, Loguercio et al[40] revealed that abnormal GGT or ALT, age and ferritin were associated with steatosis but that no single factor was found to be an independent predictor. Pagano et al[41] also said that parameters related to iron metabolism did not differ when comparing patients with NASH to the control group. Dixon et al[42] represented that there was no difference in ferritin levels between patients with NASH and without NASH. Friis-Liby et al[43] stated that abnormalities in iron indices were detected in 31 patients of 102 (39%) and elevated ferritin in 29 patients of 102 (28.4%). Pagadala et al[44] signified that elevated serum ferritin in NAFLD has not been confirmed by other studies. Chitturi et al[45], Angulo et al[46] and Younossi et al[47] did not observe any relationship between iron metabolism and the clinical or pathological outcomes in patients with NAFLD. Nevertheless, in our study high ferritin levels seemed to raise steatosis, necroinflammation and fibrosis but these results were not significant.

In conclusion, none of the present tools yield all that is needed for the “perfect” fibrosis marker as each non invasive predictor lacks accuracy and reliability and hence, combination algorithms of fibrosis markers are needed[35,39,67,68]. Although noninvasive, simple, reproducible and reliable biomarkers are still greatly needed, none of them can substitute for a liver biopsy[60].

REFERENCES

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med, 2002; 346: 1221-1231
2. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006; 40: 745-752
3. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164: 2169-2175
4. Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, Sasaki M, Nakanuma Y, Miura K, Kaneko S. Liver steatosis, but not fibrosis, is associated with insulin resistance in non-alcoholic fatty liver disease. J Gastroenterol 2007; 42: 312-317
5. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int 2011; 31: 700-706
6. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol 2011; 46 Suppl 1: 63-69
7. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010; 59: 969-974
8. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 162-168
9. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation on Obesity, Geneva, 1997 June 3-5. Geneva: World Health Organisation, 1998
10. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organisation, 1999
11. Brunt EM, Janney CG, Di Bisceglie AM. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474
12. Sobhonslidus A, Jongjirasri S, Thakkinstian A, Wisedopas N, Bunnag P, Puavilai G. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J Gastroenterol 2007; 13: 3614-3618
13. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, Goodman Z, Younoszai ZM. Predictors of non-alcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005; 15: 310-315
14. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Pouyrand T. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123
15. Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, Contos MJ, Shiffman ML, Stravitz RT, Sterling RK, Sanyal AJ. The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology 2007; 46: 1091-1100

COMMENTS

Background
Nonalcoholic fatty liver disease is a condition which is described as fat accumulation, especially triglycerides, in liver cells. This condition may lead the function of liver to deteriorate. So liver diseases including liver cirrhosis and liver failure may occur. Hence to detect this fat accumulation and to predict the probable evil outcomes are very important.

Research frontiers
To avoid the harmful consequences of NAFLD apart from liver biopsy many noninvasive methods were improved. These methods are generally based on blood tests. The studies on noninvasive methods are still going on to determine the most sensitive and specific tools. The authors also searched simple, available and reliable methods.

Innovations and breakthroughs
New predictive markers should be investigated before severe outcomes of NAFLD have occurred. This study aimed to reveal and establish simple, available and accurate noninvasive markers for liver fibrosis which are applicable in every health center.

Applications
If predictive tools could be applicable even in small health centers with high accuracy well then they are really reliable so people with fatty liver can have a check-up for prognosis of liver steatosis. The variables we used to predict liver fibrosis are even though usable and beneficial in health centers but still more investigations are needed.

Terminology
Fatty liver or liver steatosis can occur without alcohol consumption and progress to steatohepatitis which means an inflammation in liver then this condition can deteriorate so fibrous tissue begin to form after liver cell destruction. Once liver cell destruction begins somehow the event may progress to cirrhosis and liver failure. Hence to prevent this process is now an important problem and early determination of coming hazardous results of NAFLD became remarkable and developing issue in whole liver diseases.

A novel method for the "perfect" fibrosis marker as each non invasive predictor lacks accuracy and reliability and hence, combination algorithms of fibrosis markers are needed[35,39,67,68]. Although noninvasive, simple, reproducible and reliable biomarkers are still greatly needed, none of them can substitute for a liver biopsy[60].

Peer review
This descriptive study suggest that follow-up of the individuals with fatty liver should not be neglected. Especially studies on simple, accurate, reliable and above all applicable noninvasive markers for liver fibrosis in every health center should go on.
15 Angelico F, Del Ben M, Conti R, Francioso S, Feode K, Macioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver disease: a hepatic consequence of common metabolic disorders. J Gastroenterol Hepatol 2003; 18: 588-594

16 Marchesi SN, Bugini E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vannini E, Villanova N, Melchionda N, Rizzetto M. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923

17 Boza C, Riquelme A, Ibáñez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JJ, Raddatz A, Guzman S, Arrese M. Predictors of non-alcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-1153

18 Ghholm PM, Flanchbaum L, Machan JT, Charney DA, Kotler DP. Non-alcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 599-408

19 Rocha R, Cotrim HP, Bitencourt AG, Barbosa DB, Santos AS, Almeida Ade M, Cunha B, Guimarães I. Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents. World J Gastroenterol 2009; 15: 477-482

20 Gramlich T, Kleinier DE, McCullough AJ, Matteoni CA, Borapar N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004; 35: 199-206

21 Daryani NE, Daryani NE, Alavian SM, Zare A, Fereshtehnejad SM, Keramati MR, Pashaei MR, Habibollahi P. Nonalcoholic steatohepatitis and influence of age and gender on histopathologic findings. World J Gastroenterol 2010; 16: 4169-4175

22 Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res 2002; 24: 429-438

23 Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009; 51: 371-379

24 Harrison SA, Oliver D, Arnold HL, Cogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447

25 Yatsui S, Hashimoto E, Tobari M, Tokushige K, Shiratori K. Influence of age and gender in Japanese patients with nonalcoholic steatohepatitis. Hepatol Res 2007; 37: 1034-1043

26 Singh DK, Sakhuja HS, Malhotra V, Gondal R, Sarin SK. Inflammatory bowel disease: a hepatic consequence of common metabolic syndromes. J Gastroenterol Hepatol 2008; 23: 1929-1934

27 Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg 2008; 18: 847-853

28 Helling TS, Helzberg JH, Nachmani JS, Gurram K. Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated? Surg Obes Relat Dis 2008; 4: 612-617

29 Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006; 16: 1351-1358

30 Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rath PM, Joshi AS, Thakkar H, Menon PS, Shah NS. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009; 57: 205-210

31 Hossain N, Afendy A, Stepanova M, Nader F, Shrishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229, 1229.e1-1229.e2

32 Chavarria-Arceniega S, Lopez-Alvaranga JC, Uribe-Uribe NO, Herrera-Hernández M, Gonzalez-Barranco J. [Relation between morphological diagnosis of NASH (non-alcoholic steatohepatitis) and liver function tests in a group of patients with morbid obesity]. Rev Invest Clin 2005; 57: 505-512

33 Rodríguez-Hernández H, González JL, Márquez-Ramírez MD, Flores-Hernández M, Rodríguez-Morán M, Guerrero-Romero F. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes. Eur J Gastroenterol Hepatol 2008; 20: 399-403

34 Shi JP, Xun YH, Hu CB, Zhang L, Liu H, Lou GQ, Fan JG. [Clinical and histological features of non-alcoholic fatty liver disease]. Zhonghua Ganzang Bing Zazhi 2009; 17: 812-816

35 Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol 2009; 8 Suppl 1: S25-S33

36 Nomura K, Yano E, Shinozaki T, Tagawa K. Efficacy and effectiveness of liver screening program to detect fatty liver in the periodic health check-ups. J Occup Health 2004; 46: 423-428

37 Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stratvitz RT, Sanjay AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292

38 Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792-798

39 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-1269

40 Amarpurkar DN, Patel ND, Kamami PN. Evaluating risk factors for development of non-alcoholic steatohepatitis in type-II diabetes mellitus. J Hepatitis Monthly 2008; 8: 197-200

41 Bahrami H, Daryani NE, Mirmomen S, Kampangar F, Haghpanah B, Djallili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol 2003; 3: 27

42 Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1222-1224

43 Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, Foess-Wood L, Sherbodhy MA, Conjeevaram HS. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006; 101: 2247-2253

44 Amarpuraka DN, Amarpurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol 2006; 5: 30-33

45 Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-1934

46 Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Takeuchi H, Fujii K, Omatu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728

47 Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depepris N, Cassader M, David E, Cavollo-Perin P, Rizzato M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372

48 Lizardi-Cervera J, Laparaz DJ, Chavez-Tapia NC, Ostos ME, Esquivel MU. [Prevalence of NAFLD and metabolic syndrome in asymptomatic subjects]. Rev Gastroenterol Mex 2006; 71: 453-459

49 Moon KW, Leem JM, Bae SS, Lee KM, Kim SH, Chae HB, Park SM, Youn SJ. [The prevalence of metabolic syndrome in patients with nonalcoholic fatty liver disease]. Korean J Hepa-
Uslusoy HS et al. Evaluation of predictors in nonalcoholic steatohepatitis

tol 2004; 10: 197-206

50 Xanthakos S, Miles L, Bucuvalas J, Daniels S, García V, Inge T. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol 2006; 4: 226-232

51 Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379

52 Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LA, Barreto D, Gouveia L, Landeiro L. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol 2005; 17: 837-841

53 Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riedy CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96: 2957-2961

54 Marchesini G, Brizi M, Morisci-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-455

55 Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100

56 Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, Sasaki M, Nakamura Y, Miura K, Kaneko S. Liver steatosis, but not fibrosis, is associated with insulin resistance in non-alcoholic fatty liver disease. J Gastroenterol 2007; 42: 312-317

57 Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol 2005; 17: 823-826

58 Stepanova M, Aquino R, Alsheaddi A, Gupta R, Fang Y, Younossi Z. Clinical predictors of fibrosis in patients with chronic liver disease. Aliment Pharmacol Ther 2010; 31: 1085-1094

59 Pagadala M, Zein CO, McCullough AJ. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis 2009; 13: 591-606

60 Sumida Y, Eguchi Y, Ono M. Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. World J Hepatol 2010; 2: 374-383

61 Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cárdenas E, Sánchez-Avila F, Vargas-Vorácková F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008; 7: 350-357

62 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854

63 Licata A, Nebbia ME, Cabibbo G, Iacono GL, Barbazia F, Brucato V, Alessi N, Porrovecchio S, Di Marco V, Craxi A, Cammà C. Hyperferritinemia is a risk factor for steatosis in chronic liver disease. World J Gastroenterol 2009; 15: 2132-2138

64 Loguercio C, De Simone T, D’Auria MV, de Sio I, Federico A, Tuccioli C, Abbatecola AM, Del Vecchio Blanco C. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 2004; 36: 398-405

65 Friis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Börnson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2009; 44: 864-869

66 Younossi ZM, Cranlitch T, Bacon BR, Matteoni CA, Boparai N, O’Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-850

67 Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589

68 Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis 2008; 28: 386-395

69 Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but do not substitute the need for liver biopsy. World J Gastroenterol 2006; 12: 3682-3694

70 Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 259-259

S-Editor Zhang SJ  L-Editor Roemmele A  E-Editor Zheng XM